TRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Company Contact: | Investor Contact: |
Patricia Bitar | Andrew McDonald |
Chief Financial Officer | LifeSci Advisors LLC |
(858) 550‐0780 ext. 223 | 646-597-6987 |
pbitar@traconpharma.com | Andrew@lifesciadvisors.com |
Source: TRACON Pharmaceuticals, Inc.